IMMX NASDAQ
Immix Biopharma, Inc.
1W: -1.9%
1M: -26.5%
3M: -4.5%
YTD: +48.4%
1Y: +135.0%
3Y: +185.8%
$8.05
-0.01 (-0.12%)
After Hours: $8.32 (+0.27, +3.35%)
Weekly Expected Move ±9.7%
$7
$7
$8
$9
$10
Credit Risk of going bust: lower than 73% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Immix Biopharma, Inc. would be worth roughly what it owes.
Total debt $1.0M against a stock market value of $668.2M.
Distance to default 8.21 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $501K (short-term plus half of long-term), stock volatility 84.0%; Altman Z'' 26.88. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Immix Biopharma, Inc. would be worth roughly what it owes.
Total debt $1.0M against a stock market value of $668.2M.
Distance to default 8.21 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $501K (short-term plus half of long-term), stock volatility 84.0%; Altman Z'' 26.88. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.45
Bullish
1 bullish
1 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (39)
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Immix Biopharma, Inc. (NASDAQ:IMMX) Stock Has Average Price Target of $24.29
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 5.7% – Should You Sell?
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma (NASDAQ:IMMX) Stock Jumps 4.1% – Should You Buy?
Immix rises after new mid-stage trial data for AL amyloidosis therapy
Immix Biopharma prices $125M stock offering
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
Bank of America Corp DE Makes New $4.26 Million Investment in Immix Biopharma, Inc. $IMMX
Immix Biopharma, Inc. (NASDAQ:IMMX) Stock Has Consensus Target Price of $22.86 According to Brokerages
Analysts Set Immix Biopharma, Inc. (NASDAQ:IMMX) Price Target at $21.29
Immix Biopharma (NASDAQ:IMMX) Reaches New 12-Month High – Still a Buy?
Brokerages Set Immix Biopharma, Inc. (NASDAQ:IMMX) Target Price at $20.71
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Brokerages Set Immix Biopharma, Inc. (NASDAQ:IMMX) Price Target at $20.67
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
What's Going On With Immix Biopharma Stock Thursday?
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
Brokerages Set Immix Biopharma, Inc. (NASDAQ:IMMX) Price Target at $18.25
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Immix rises as Morgan Stanley starts with bullish view on CAR-T therapy
Analysts Set Immix Biopharma, Inc. (NASDAQ:IMMX) PT at $15.00
This Valaris Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
This Truist Financial Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Immix Biopharma to Participate in Upcoming Investor Conferences
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis